secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001493152-23-029604
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell shareholders approve spinout of BriaPro Therapeutics with 98.9% support
--------------------------------------------------------------------------------

- Shareholders approved Arrangement to spin out BriaPro Therapeutics (Bria-TILsRx, PKCδ inhibitors) with 98.92% votes.
- SpinCo will be a 2/3 owned subsidiary of BriaCell; each share gets one SpinCo share and one new BriaCell share.
- Closing expected on/around Aug 31, 2023, subject to final court approval on Aug 25 and regulatory approvals.
- SpinCo Option Plan approved (89.70% votes); August 2022 option grant ratified (99.10% votes).
- BriaCell remains listed on NASDAQ/TSX; SpinCo will become an unlisted reporting issuer in Canada.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223029604/0001493152-23-029604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223029604/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer